The incidence of cerebral glioma in the working population: a forgotten cancer?

Grant, Robin; Collie, Donald A.; Counsell, Carl

doi:10.1038/bjc.1996.44

Cited by 5 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,20 The demographic characteristics of glioma patients in the Lancashire and South Cumbria region are similar to those of glioma patients in other populations, with significantly more males than females affected 21 and onset often in middle adulthood in men and women of working age. 2 Predominance of glioblastomas is seen universally, and the site distribution within the brain is similar to that reported in other series with respect to frontal and parietal lobe dominance, although some differences are noted in comparison with a detailed single-center study in Finland, 22 which may not have been a representative series.…”

Section: Discussionsupporting

confidence: 75%

“…This stability and consistency are confirmed by published reports of regional incidence of glioma across England and Scotland during the last 2 decades. 2,7,18 Indeed, the observed lack of any increase in rates is in line with trends of gliomas in Nordic countries 6 and in the United States. 19,20 These stable trends are interpreted as evidence of a lack of association between mobile phone use, which has risen rapidly in this period, and the occurrence of malignant brain tumors.…”

Section: Discussionsupporting

confidence: 67%

“…They account for 2% of all cancers diagnosed, but the 5-year survival rates are the fourth lowest of the 21 most common cancers in England. 1 Moreover, brain tumors affect a disproportionately high number of people of working age (less than aged 65 years) 2 and are the third most common cause of cancer death in the age group 15 -34 years. The majority (86%) of brain tumors are gliomas, 3,4 and these have a poor prognosis with median survival of around 12 months and ,3% of patients surviving for 5 years.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Incidence of glioma in a northwestern region of England, 2006-2010

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionsupporting

confidence: 67%

mentioning

confidence: 99%

See 1 more Smart Citation

Incidence of glioma in a northwestern region of England, 2006-2010

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Malignant gliomas can occur at any age but most commonly after the age of 40. Their peak incidence is between 65 and 75 years of age [9] [10].…”

mentioning

confidence: 99%

Follistatin, a Novel Biomarker for Malignant Gliomas

Lekka¹,

Tsesmetzis²,

Ashton³

et al. 2015

View full text Add to dashboard Cite

Molecular biomarkers are commonly used for the management of several types of malignant tumours in routine clinical practice. However, this is not the case for malignant gliomas. Cytokines and Angiogenesis factors are potential candidates due to their intrinsic role in tumourigenesis. Pre-and post-operative serum from 36 malignant glioma patients and 36 controls was analysed using the Bio-Plex Pro Angiogenesis and Cytokines Assay (Bio-Rad, USA). Amongst the molecules tested, the serum concentration of follistatin was significantly higher in patients than in controls. Moreover, the serum concentration of follistatin of the patients postoperatively was significantly reduced compared to that preoperatively. Factors such as age and gender did not affect the concentrations of follistatin measured in the serum of patients pre-and post-operatively as well as healthy controls. This is the first report of follistatin as potential biomarker for the detection of malignant gliomas.

show abstract

Anatomical and biochemical investigation of primary brain tumours

Sole

Falini

Ravasi³

et al. 2001

Eur J Nucl Med

View full text Add to dashboard Cite

Cancerous transformation entails major biochemical changes including modifications of the energy metabolism of the cell, e.g. utilisation of glucose and other substrates, protein synthesis, and expression of receptors and antigens. Tumour growth also leads to heterogeneity in blood flow owing to focal necrosis, angiogenesis and metabolic demands, as well as disruption of transport mechanisms of substrates across cell membranes and other physiological boundaries such as the blood-brain barrier. All these biochemical, histological and anatomical changes can be assessed with emission tomography, X-ray computed tomography (CT), magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). Whereas anatomical imaging is aimed at the diagnosis of brain tumours, biochemical imaging is better suited for tissue characterisation. The identification of a tumoural mass and the assessment of its size and vascularisation are best achieved with X-ray CT and MRI, while biochemical imaging can provide additional information that is crucial for tumour classification, differential diagnosis and follow-up. As the assessment of variables such as water content, appearance of cystic lesions and location of the tumour are largely irrelevant for tissue characterisation, a number of probes have been employed for the assessment of the biochemical features of tumours. Since biochemical changes may be related to the growth rate of cancer cells, they can be thought of as markers of tumour cell proliferation. Biochemical imaging with radionuclides of processes that occur at a cellular level provides information that complements findings obtained by anatomical imaging aimed at depicting structural, vascular and histological changes. This review focusses on the clinical application of anatomical brain imaging and biochemical assessment with positron emission tomography, single-photon emission tomography and MRS in the diagnosis of primary brain tumours, as well as in follow-up.

show abstract

The incidence of cerebral glioma in the working population: a forgotten cancer?

Cited by 5 publications

References 2 publications

Incidence of glioma in a northwestern region of England, 2006-2010

Incidence of glioma in a northwestern region of England, 2006-2010

Follistatin, a Novel Biomarker for Malignant Gliomas

Anatomical and biochemical investigation of primary brain tumours

Contact Info

Product

Resources

About